# Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes

> **NCT00791479** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 167 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** LY2189265 and Lifestyle Measures
- **DRUG:** Placebo solution and Lifestyle Measures

## Key facts

- **NCT ID:** NCT00791479
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2014-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00791479

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00791479, "Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT00791479. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*